Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer.
Wang L, Wu YL, Lu S, Deng L, Ahn MJ, Hsu FM, Iscoe N, Hossain A, Puri T, Zhang P, Orlando M. Wang L, et al. Among authors: puri t. Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ajco.12513. Epub 2016 Jun 17. Asia Pac J Clin Oncol. 2016. PMID: 27312514 Clinical Trial.
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up.
Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Koppiker CB, Xue FC, Barraclough H, Dhindsa N, Seth A, Majumdar A, Puri T. Julka PK, et al. Among authors: puri t. Breast Cancer. 2013 Oct;20(4):357-62. doi: 10.1007/s12282-012-0343-4. Epub 2012 Feb 22. Breast Cancer. 2013. PMID: 22354450 Clinical Trial.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study.
Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. Yang JC, et al. Among authors: puri t. J Thorac Oncol. 2016 Mar;11(3):370-9. doi: 10.1016/j.jtho.2015.11.008. Epub 2015 Dec 25. J Thorac Oncol. 2016. PMID: 26725183 Free article. Clinical Trial.
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N, Yang JC. Boye M, et al. Among authors: puri t. Clin Lung Cancer. 2016 Mar;17(2):150-60. doi: 10.1016/j.cllc.2015.12.004. Epub 2015 Dec 17. Clin Lung Cancer. 2016. PMID: 26809984 Free article. Clinical Trial.
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).
Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, Lee P, Alexandris E, Puri T, Orlando M. Park K, et al. Among authors: puri t. Cancer Res Treat. 2016 Oct;48(4):1177-1186. doi: 10.4143/crt.2015.401. Epub 2016 Feb 22. Cancer Res Treat. 2016. PMID: 26910471 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Cheng Y, et al. Among authors: puri t. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9. J Clin Oncol. 2016. PMID: 27507876 Clinical Trial.
Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al.
Yang JC, Puri T, Orlando M, Cheng Y. Yang JC, et al. Among authors: puri t. J Clin Oncol. 2017 Feb 20;35(6):694-695. doi: 10.1200/JCO.2016.70.6978. Epub 2016 Dec 5. J Clin Oncol. 2017. PMID: 27918723 No abstract available.
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M. Park K, et al. Among authors: puri t. Cancer Res Treat. 2017 Oct;49(4):937-946. doi: 10.4143/crt.2016.423. Epub 2017 Jan 6. Cancer Res Treat. 2017. PMID: 28111429 Free PMC article. Clinical Trial.
112 results